InsidersTradesSigma
Follow the EDGEWISE THERAPEUTICS INC stock price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €4.6bn. The latest transaction was filed on 13 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: JOANNE DONOVAN. The full history is openly available.
Analysts rate EDGEWISE THERAPEUTICS INC Buy (bullish), based on 13 analysts. Average price target: US$51.69.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
EDGEWISE THERAPEUTICS INC 是一家生物制药公司，专注于开发罕见遗传疾病的治疗方法。它采用创新方法设计靶向疗法。